Advanced search
Publication Cover
Postgraduate Medicine Volume 125, 2013 - Issue 2
Submit an article Journal homepage
72
Views
6
CrossRef citations to date
0
Altmetric
Clinical Features

Efficacy of Amlodipine/Olmesartan Medoxomil ± Hydrochlorothiazide in Patients Aged ≥ 65 or < 65 Years With Uncontrolled Hypertension on Prior Monotherapy

Matthew R. Weir Director, Division of Nephrology, University of Maryland School of Medicine, Baltimore, MDCorrespondence[email protected]
, MD,
Ali Shojaee Manager, Scientific Communications, Daiichi Sankyo, Inc., Parsippany, NJ
, PharmD &
Jen-Fue Maa Associate Director, Biostatistics and Data Management, Daiichi Sankyo, Inc., Parsippany, NJ
, PhD
Pages 124-134 | Published online: 13 Mar 2015

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Peter Bramlage, Eva-Maria Fronk, Wolf-Peter Wolf, Rüdiger Smolnik, Gemma Sutton & Roland E Schmieder. (2015) Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. Vascular Health and Risk Management 11, pages 1-8.
Read now

Articles from other publishers (5)

Ju Hyeon Kim, Hyung Joon Joo, Se Hwa Chung, Yunjin Yum, Yong Hyun Kim & Eung Ju Kim. (2023) Safety and cardiovascular effectiveness of olmesartan in combination therapy for advanced hypertension: an electronic health record-based cohort study. Journal of Hypertension 41:10, pages 1578-1584.
Crossref
Luis M. Ruilope & Gema Ruiz-Hurtado. (2019) Monotherapy still useful in a bunch of patients with arterial hypertension. International Journal of Cardiology 291, pages 119-120.
Crossref
Prakash Deedwania, Michael Weber, Paul-Egbert Reimitz & George Bakris. (2017) Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. The Journal of Clinical Hypertension 19:12, pages 1309-1318.
Crossref
Antonia C. Wang, Ulf Stellmacher, Jennifer Schumi, Nora Tu & Paul-Egbert Reimitz. (2016) Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data. American Journal of Cardiovascular Drugs 16:6, pages 427-437.
Crossref
Jeanne Mendell, Nobuko Matsushima, Terry E. O'Reilly & James Lee. (2015) A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval. The Journal of Clinical Pharmacology 56:4, pages 484-491.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.